Stocks and Investing Stocks and Investing
Tue, January 5, 2016
Mon, January 4, 2016
Wed, December 30, 2015
Tue, December 29, 2015
Mon, December 28, 2015
Wed, December 23, 2015
Tue, December 22, 2015
Mon, December 21, 2015
Fri, December 18, 2015
Thu, December 17, 2015
Wed, December 16, 2015
Tue, December 15, 2015
Mon, December 14, 2015
Fri, December 11, 2015
Thu, December 10, 2015
Wed, December 9, 2015
Tue, December 8, 2015
Mon, December 7, 2015
Fri, December 4, 2015
Thu, December 3, 2015
Wed, December 2, 2015
Tue, December 1, 2015

Paul Matteis Initiated (VRTX) at Strong Buy and Held Target at $125 on, Dec 1st, 2015


Published on 2024-10-25 10:41:13 - WOPRAI, Paul Matteis
  Print publication without navigation


Paul Matteis of Stifel, Initiated "Vertex Pharmaceuticals Incorporated" (VRTX) at Strong Buy and Held Target at $125 on, Dec 1st, 2015.

Paul has made no other calls on VRTX in the last 4 months.



There are 4 other peers that have a rating on VRTX. Out of the 4 peers that are also analyzing VRTX, 1 agrees with Paul's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Biren Amin of "Jefferies" Initiated at Hold and Held Target at $130 on, Wednesday, September 9th, 2015


These are the ratings of the 3 analyists that currently disagree with Paul


  • Andrew Fein of "HC Wainwright & Co." Upgraded from Hold to Strong Buy and Increased Target to $155 on, Friday, October 30th, 2015
  • Matthew Harrison of "Morgan Stanley" Upgraded from Hold to Buy and Increased Target to $148 on, Friday, October 2nd, 2015
  • Jasper Hellweg of "Argus Research" Upgraded from Hold to Strong Buy on, Monday, September 28th, 2015